Home / Going-concern warnings / Karyopharm Therapeutics Inc.
Filed 2026-02-13 路 Form 10-K 路 Accession 0001193125-26-049397 micro
Price before filing: $8.94 (2026-02-12 close, split/dividend-adjusted)
Market cap at flag: $188.9M (2026-02-13) 路 Latest: $11.3M (2026-10-16)
| Window | KPTI | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -4.4% | -1.8% | -2.6% | 2026-03-16 |
| 90 days | -0.4% | +10.1% | -10.6% | 2026-05-14 |
| 180 days | -77.3% | +14.0% | -91.3% | 2026-08-12 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
90 days before the flag: 2 insiders sold $12K (3 sales)
30 days after: 6 insiders sold $297K (7 sales)
| Date | Insider | Type | Shares | Price | Value | 10b5-1 plan | Source |
|---|---|---|---|---|---|---|---|
| 2026-01-21 | Abate Kristin Chief Accounting Officer | Sale | 265 | $5.96 | $2K | no | Form 4 |
| 2026-01-28 | Abate Kristin Chief Accounting Officer | Sale | 50 | $7.03 | $352 | no | Form 4 |
| 2026-02-03 | Macomber Lori EVP, CFO & Treasurer | Sale | 1,626 | $6.30 | $10K | no | Form 4 |
| 2026-02-13: red flag filed | |||||||
| 2026-02-17 | Poulton Stuart EVP, Chief Development Officer | Sale | 378 | $8.63 | $3K | no | Form 4 |
| 2026-03-02 | Abate Kristin Chief Accounting Officer | Sale | 559 | $9.41 | $5K | no | Form 4 |
| 2026-03-02 | Cheng Sohanya Roshan EVP & Chief Commercial Officer | Sale | 4,604 | $9.41 | $43K | no | Form 4 |
| 2026-03-02 | Mano Michael EVP, CLO&Secretary | Sale | 3,526 | $9.41 | $33K | no | Form 4 |
| 2026-03-02 | Paulson Richard A. President and CEO, Director | Sale | 12,361 | $9.41 | $116K | no | Form 4 |
| 2026-03-02 | Poulton Stuart EVP, Chief Development Officer | Sale | 5,101 | $9.41 | $48K | no | Form 4 |
| 2026-03-02 | Rangwala Reshma EVP & Chief Medical Officer | Sale | 5,066 | $9.41 | $48K | no | Form 4 |
Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2025-11-15 to 2026-03-15. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.
"As discussed in Note 1 to the financial statements, the Company has incurred significant operating losses since inception, expects to incur significant operating losses for the foreseeable future and has stated that substantial doubt exists about the Company's ability to continue as a going concern."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Going-concern opinion issued by: Ernst & Young LLP
Source: independent auditor report in Form 10-K (period 2025-12-31)
Why this score: in auditor's report
Read the original filing on SEC.gov →
🔔 Get email alerts for this company
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.